The Australian Parkinson’s Mission employs an entirely new design for Parkinson’s. The findings from our clinical trials will be integrated with analyses of patients’ genomic information and biomarkers – naturally occurring measurable indicators of a disease. This will help us identify the right drug for the right patient at the right time to halt this disease.Associate Professor Antony Cooper, Head of Neurodegeneration and Neurogenomics at the Garvan Institute, and iLCT committee member
We are sorry that this content was not useful for you
Let us improve this content
Can you tell us how we can improve this content?